3,6,9,12,15-Pentaoxaoctadec-17-ynoic acid

 CAS No.: 1429934-37-1  Cat No.: BP-501356  Purity: ≥95% 4.5  

3,6,9,12,15-Pentaoxaoctadec-17-ynoic acid is a PEG-like, ether-rich alkyne-containing linker acid featuring five internal ethylene-oxide units that provide conformational flexibility and improved aqueous compatibility, together with a terminal carboxylic acid for controlled conjugation. The alkyne functionality enables orthogonal chemical handles for subsequent coupling strategies (e.g., click-type or other alkyne-compatible chemistries), while the extended ether chain acts as a spacer to reduce steric interference between a targeting ligand and an E3-recruiting moiety in PROTAC constructs. In targeted protein degradation design, such flexible, oxygenated linkers are commonly used to tune effective reach, maintain productive ternary complex formation, and mitigate unfavorable intramolecular contacts that can lower degradation efficiency. As a modular linker building block, this acid supports systematic optimization of linker length and polarity, facilitating structure–activity relationship studies in PROTAC synthesis and enabling reproducible preparation of degraders for mechanistic and cellular evaluation.

3,6,9,12,15-Pentaoxaoctadec-17-ynoic acid

Structure of 1429934-37-1

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
PROTAC Linker
Molecular Formula
C13H22O7
Molecular Weight
290.31
Appearance
Pale Yellow Oily Matter

* For research and manufacturing use only. Not for human or clinical use.

SizePriceStockQuantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

  • Comprehensive PROTAC Platform
  • Scientific Expertise & Technical Support
  • Custom Synthesis & Design Service
  • Extensive Product Coverage
  • Cutting-Edge Innovation
  • Fast Delivery & Global Support
  • 24/7 customer service
  • 100% quality assurance
Popular Publications Citing BOC Sciences Products
Purity
≥95%
Solubility
Soluble in DMSO
Appearance
Pale Yellow Oily Matter
Storage
Store at 2-8°C for short term (days to weeks) or -20°C for long term (months to years)
Shipping
Room temperature in continental US; may vary elsewhere.
IUPACName
2-[2-[2-[2-(2-prop-2-ynoxyethoxy)ethoxy]ethoxy]ethoxy]acetic acid
Synonyms
Propargyl-PEG5-CH2CO2H;Propargyl-PEG5-CH2COOH; Propargyl-PEG4-CH2COOH; 3,6,9,12,15-Pentaoxaoctadec-17-yn-1-oic acid
Boiling Point
413.7±40.0°C at 760 mmHg
Density
1.1±0.1 g/cm3
InChI Key
QOUMZZIPISUGKO-UHFFFAOYSA-N
InChI
InChI=1S/C13H22O7/c1-2-3-16-4-5-17-6-7-18-8-9-19-10-11-20-12-13(14)15/h1H,3-12H2,(H,14,15)
SMILES
C#CCOCCOCCOCCOCCOCC(=O)O
1. Bone Marrow Aspirate Concentrate Is Equivalent to Platelet-Rich Plasma for the Treatment of Knee Osteoarthritis at 2 Years: A Prospective Randomized Trial
Adam W Anz, Hillary A Plummer, Achraf Cohen, Peter A Everts, James R Andrews, Joshua G Hackel Am J Sports Med. 2022 Mar;50(3):618-629.doi: 10.1177/03635465211072554.
Background:Autologous platelet-rich plasma (PRP) and bone marrow aspirate concentrate (BMC) are being used clinically as therapeutic agents for the treatment of knee osteoarthritis.Purpose/hypothesis:The purpose of this study was to compare the efficacy of BMC and PRP on pain and function in patients with knee osteoarthritis up to 24 months after injection. It was hypothesized that patients receiving BMC would have better sustained outcomes than those receiving PRP.Study design:Randomized controlled trial; Level of evidence, 2.
2. Caffeine Improves Triathlon Performance: A Field Study in Males and Females
Sunita Potgieter, Hattie H Wright, Carine Smith Int J Sport Nutr Exerc Metab. 2018 May 1;28(3):228-237.doi: 10.1123/ijsnem.2017-0165.Epub 2018 Jun 1.
The ergogenic effect of caffeine on endurance exercise is commonly accepted. We aimed to elucidate realistically the effect of caffeine on triathlon event performance using a field study design, while allowing investigation into potential mechanisms at play. A double-blind, randomized, crossover field trial was conducted. Twenty-six triathletes (14 males and 12 females; mean ± SD: age = 37.8 ± 10.6 years, habitual caffeine intake = 413 ± 505 mg/day, percentage body fat = 14.5 ± 7.2%, and training/week = 12.8 ± 4.5 hr) participated in this study. Microencapsulated caffeine (6 mg/kg body weight) was supplemented 60 min pretrial. Performance data included time to completion, rating of perceived exertion, and profile of mood states. Blood samples taken before, during, and postrace were analyzed for cortisol, testosterone, and full blood count. Capillary blood lactate concentrations were assessed prerace, during transitions, and 3, 6, 9, 12, and 15 min after triathlons. Caffeine supplementation resulted in a 3.7% reduction in swim time (33.5 ± 7.0 vs. 34.8 ± 8.1 min, p < .05) and a 1.3% reduction in time to completion (149.6 ± 19.8 vs. 151.5 ± 18.6 min, p < .05) for the whole group. Gender differences and individual responses are also presented. Caffeine did not alter the rating of perceived exertion significantly, but better performance after caffeine supplementation suggests a central effect resulting in greater overall exercise intensity at the same rating of perceived exertion. Caffeine supplementation was associated with higher postexercise cortisol levels (665 ± 200 vs. 543 ± 169 nmol/L, p < .0001) and facilitated greater peak blood lactate accumulation (analysis of variance main effect, p < .05). We recommend that triathlon athletes with relatively low habitual caffeine intake may ingest 6 mg/kg body weight caffeine, 45-60 min before the start of Olympic-distance triathlon to improve their performance.
3. The relationship of asprosin with β-hydroxybutyric acid and postpartum disorders in cows
Mehmet Akif Kilinc, Ali Risvanli Acta Vet Hung. 2022 Jan 24.doi: 10.1556/004.2022.00002.Online ahead of print.
The aim of the present study was to determine asprosin levels in cows, the relationship of this hormone with postpartum disorders and β-hydroxybutyric acid, and also the potential of asprosin to be a marker for postpartum diseases. The study was designed as a two-stage trial. In the first stage, blood asprosin and β-hydroxybutyric acid levels of 20 healthy Simmental cows aged 3-4 years were measured at the time of calving, and on days 3, 6, 9, 12 and 15 postpartum. In the second stage, 200 cows were divided into two groups: (1) healthy (n = 100) and (2) diseased (placental retention, hypocalcaemia, metritis, lameness, abomasal displacement, mastitis; n = 100); asprosin and β-hydroxybutyric acid concentrations of the blood were assessed on day 15 postpartum. In conclusion, the asprosin level was found to be at measurable levels in cows, and a negative correlation with β-hydroxybutyric acid was found. According to these findings, the data obtained from this study could be used for the prevention, control and treatment of some postpartum disorders associated with ketosis and for developing novel hypotheses concerning the actions of this hormone. It was concluded that further studies are required to reveal the associations between asprosin and postpartum disorders.

This PROTAC linker, 3,6,9,12,15-Pentaoxaoctadec-17-ynoic acid, provides a polyethylene-oxide–like, flexible spacing element that can be incorporated into targeted protein degradation constructs to tune linker length, solvation, and ternary-complex formation. Its terminal carboxylic acid enables robust conjugation strategies to install warheads and E3 ligase-binding ligands. The detailed structural and synthetic considerations are provided below.

Structure: The molecule is an alkyne-containing, ether-rich chain featuring multiple internal oxygen atoms that impart conformational flexibility and polarity. A terminal carboxylic acid provides a chemically defined functional handle for amide or ester formation, while the carbon–carbon triple bond offers a stable, non-oxidizing linkage point under typical coupling conditions.

Reactivity: The carboxylic acid is well suited for standard PROTAC linker coupling via amide bond formation using activated carboxyl derivatives (for example, acid chlorides or carbodiimide-mediated activation) with amine-bearing partners. Typical conditions employ polar aprotic solvents and base to promote condensation. The alkyne generally tolerates these transformations without requiring specialized catalysts, enabling sequential assembly of bifunctional PROTAC intermediates under controlled, anhydrous handling.

Stock concentration: *
Desired final volume: *
Desired concentration: *

L

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2

* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
g/mol
g

Related Product Recommendations

BOC Sciences Support

Please contact us with any specific requirements and we will get back to you as soon as possible.


  • Verification code
Inquiry Basket